Abstract: Objective To test and compare CA19-9,CEA with Specific N-Glycans in early-middle stage pancreatic carcinoma serum to find a better tumor marker in early pancreatic carcinoma.Methods To find the difference of N-Glycans structure,DSA-FACE was performed in 35 early middle stage pancreatic carcinoma patients and 50 healthy human.Meanwhile,we tested CA19-9 and CEA in the pancreatic carcinoma patients at the same stage.Result The serum N-glycan profiles of pancreatic carcinoma was identified by the DSA-FACE technique.The Results showed that between pancreatic carcinoma patients and healthy persons,there were significant differences in N-glycans.The peak 13,14 and 17 were the most significant peaks which would be most likely picked as a new tumor marker of pancreatic carcinoma.Taking log(p14×p17/p13)as indicator of the ROC curve analysis,and the area under ROC curve was 0.799±0.050 with 84.9% sensitivity and 68% specificity.Meanwhile,the sensitivity of CA19-9 was 61.2%,the sensitivity of CEA was 11.7%.Conclusion The Peak 13,14 and 17 are the most significant peaks which would be picked as a new tumor marker of pancreatic carcinoma.Espicially,its sensitivity is superior to CA19-9、CEA for early middle stage patients.